[{"id":"2ca1ff45-c374-4801-b9ec-433565778ed7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04675060","created_at":"2021-01-19T20:45:37.210Z","updated_at":"2024-07-02T16:36:32.534Z","phase":"Phase 1","brief_title":"Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules","source_id_and_acronym":"NCT04675060","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" ALK • MET • ROS1","pipe":" | ","alterations":" MET amplification • ALK fusion • ALK mutation • ROS1 fusion • MET mutation • ALK-ROS1 fusion","tags":["ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • ALK fusion • ALK mutation • ROS1 fusion • MET mutation • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anluoqing (envonalkib)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/23/2021","start_date":" 02/23/2021","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2021-04-01"},{"id":"3d344046-9a19-4ecf-8ba0-b860fd756edb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04056572","created_at":"2021-01-18T19:53:09.565Z","updated_at":"2024-07-02T16:36:54.123Z","phase":"Phase 2","brief_title":"Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib","source_id_and_acronym":"NCT04056572","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Anluoqing (envonalkib)"],"overall_status":"Unknown status","enrollment":" Enrollment 135","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 10/30/2021","primary_completion_date":" 10/30/2021","study_txt":" Completion: 04/30/2022","study_completion_date":" 04/30/2022","last_update_posted":"2019-10-30"},{"id":"e66573c6-4c6e-4f7a-8154-ed87cbf7499d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04009317","created_at":"2021-01-18T19:41:58.760Z","updated_at":"2024-07-02T16:36:54.134Z","phase":"Phase 3","brief_title":"Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04009317","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Anluoqing (envonalkib)"],"overall_status":"Unknown status","enrollment":" Enrollment 260","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 10/30/2021","primary_completion_date":" 10/30/2021","study_txt":" Completion: 04/30/2022","study_completion_date":" 04/30/2022","last_update_posted":"2019-10-30"}]